Publications & Presentations

Check out the latest scientific presentations from Kailera Therapeutics.

HRS-7535, an Oral Small-Molecule GLP-1 Receptor Agonist, in Chinese Adults with Obesity without Diabetes: a Randomized, Double-blind, Placebo-controlled Phase 2 Trial

J. Wu et al.
Nature Communications, June 2026
June 2026

A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel GLP-1/GIP Receptor Dual Agonist in Development for People Living with Overweight/Obesity

L. Klickstein et al.
American Diabetes Association (ADA) 2026
June 2026

Efficacy and Safety of Oral Ribupatide (HRS9531) in Chinese Adults with Obesity: A Phase 2 Trial

Z. Ye et al.
American Diabetes Association (ADA) 2026
June 2026

Efficacy and Safety of HRS9531, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults Living with Overweight or Obesity Without Diabetes

X. Li et al.
ObesityWeek® 2025
November 2025

Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA (HRS-7535) in Chinese Patients with Type 2 Diabetes Inadequately Controlled by Metformin and SGLT2 Inhibitor

M. Ren et al.
European Association for the Study of Diabetes (EASD)
September 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Chinese Adults with Overweight or Obesity Without Diabetes

Q. Wen et al.
European Association for the Study of Diabetes (EASD)
September 2025

Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide-1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin

L. Guo et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide-1 Receptor Agonist (HRS-7535) in Chinese Adults with Obesity without Diabetes

W. Gu et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Participants with Type 2 Diabetes Mellitus (T2DM): a Randomized, Double-Blind, Placebo Controlled Phase 2 Trial

J. Zhao et al.
American Diabetes Association (ADA) 2025
June 2025